Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Fate Therapeutics (NQ: FATE )

75.26 USD -2.73 (-3.50%)
Streaming Delayed Price Updated: 3:46 PM EDT, Apr 12, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Fate Therapeutics

< Previous 1 2 3 4 5 6 7 8 9 Next >
Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service
From GlobeNewswire News Releases
Fate Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress
From GlobeNewswire News Releases
Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
From GlobeNewswire News Releases
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2020 Financial Results
From GlobeNewswire News Releases
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From GlobeNewswire News Releases
Fate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From GlobeNewswire News Releases
Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock
From GlobeNewswire News Releases
Thinking about buying stock in Pfizer, Moderna, Oncternal Therapeutics, Fate Therapeutics, or Atara Biotherapeutics?
InvestorsObserver issues critical PriceWatch Alerts for PFE, MRNA, ONCT, FATE, and ATRA. 
From PR Newswire
Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma
From GlobeNewswire News Releases
Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma
From GlobeNewswire News Releases
Fate Therapeutics to Host Virtual Event at the 2020 ASH Annual Meeting
From GlobeNewswire News Releases
Fate Therapeutics Announces Participation in Upcoming Investor Conferences
From GlobeNewswire News Releases
Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress
From GlobeNewswire News Releases
Fate Therapeutics Announces Twelve Presentations at the 2020 ASH Annual Meeting
From GlobeNewswire News Releases
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2020 Financial Results
From GlobeNewswire News Releases
Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting
From GlobeNewswire News Releases
Fate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit
From GlobeNewswire News Releases
Fate Therapeutics Announces September Investor Events
From GlobeNewswire News Releases
Increased Insider Transactions Signals Bullish Stocks: $GTES $PSN $FATE
Tags The Market Signal
From The Market Signal
Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer
From GlobeNewswire News Releases
Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress
From GlobeNewswire News Releases
Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference
From GlobeNewswire News Releases
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results
From GlobeNewswire News Releases
Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies
From GlobeNewswire News Releases
Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy
From GlobeNewswire News Releases
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From GlobeNewswire News Releases
Fate Therapeutics Announces Pricing of Public Offering of Common Stock
From GlobeNewswire News Releases
Fate Therapeutics Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.